Dopamine receptors have been associated with many neurological disorders, including most notably Parkinson’s disease and schizophrenia. SCH 23390 is a highly potent and selective dopamine D1-like receptor antagonist with a Ki of 0.2 and 0.3 nM for the D1 and D5 dopamine receptor subtypes, respectively. SCH 23390 HCl is the hydrochloride form of SCH 23390. SCH 23390 also binds with high affinity to the 5-HT2 and 5-HT1C serotonin receptor subtypes[1]. Intra-DLS (dorsolateral striatum) microinfusion of SCH23390 (100 ng) or sulpiride both increased anxiety, indicated by increases in time spent in the enclosed maze arms in rats, while intra-DMS (dorsomedial striatum) microinfusion of SCH23390, sulpiride, or saline did not affect performance in a novelty preference test, indicated by greater time spent in a ‘novel’ maze arm compared to ‘non-novel’ arms[2]. In contextual fear conditioning and memory testing, SCH23390 (0.1 mg/kg) given before conditioning or before both conditioning and retrieval decreased freezing at retrieval, whereas SCH23390 given only before retrieval had no effect. SCH23390 (2.5 μg/0.5 uL) infused into dmPFC (dorsomedial prefrontal cortex) before conditioning decreased freezing at retrieval, while infusion of SCH23390 into NAc (nucleus accumbens) or VH (ventral hippocampus) had no effect[3].
搜索
